←
John Santini5 posts
John Santini avatar

John Santini

@jsantini1
◷ Joined January 2010
Vergent Bioscience avatar
⟳ John Santini retweeted
Vergent Bioscience@VergentBio·Jun 9

Vergent Bioscience names Adam Gridley President & CEO. John Santini, PhD, moves to CTO to lead platform expansion as we advance a Phase 3 study evaluating abenacianine for tumor visualization during lung cancer surgery. Read more: bit.ly/43kDXu7 #Leadership

Post attachment
John Santini avatar
John Santini@jsantini1·13 Dec 2023

The VISUALIZE study is an exciting next step for VGT-309 and we look forward to further evaluating its utility in lung cancer surgery.

#NEWS: The first patients have been enrolled in our Phase 2 multi-center VISUALIZE study! The study will assess the potential of our tumor-targeted fluorescent imaging agent, VGT-309, to improve visibility of tumors during lung cancer surgery. Read more: vergentbio.com/vergent-bio-i… #clinicaltrials #medtwitter #meded

Post attachment
John Santini avatar
John Santini@jsantini1·11 Sep 2023

It was great to have so many attendees at Dr. Wright's presentation of phase 2 VGT-309 study data earlier today. #WCLC23 @IASLC

Today we presented new data at the @IASLC 2023 World Conference on #LungCancer providing compelling evidence that VGT-309 increases the potential that surgeons can identify all tumor tissue during minimally invasive and robotic surgery. #WLCL23 Read more: vergentbio.com/news-2023-sep…

Post attachment
John Santini avatar
John Santini@jsantini1·29 Nov 2022

We are grateful to the NCI and the team at Penn for their support of our Phase 2 trial of VGT-309 in lung cancer.

We’ve been awarded a Small Business #Innovation Research grant from @NIH. This will support our study of targeted fluorescent imaging agent to improve #tumorvisualization. Read the announcement: https://t.co/eNPluLal6i

0:15
John Santini avatar
John Santini@jsantini1·4 Oct 2022

Previous clinical studies have validated the potential of VGT-309, and these additional funds will enable us to efficiently advance our current and future clinical trials in #LungCancer.

Vergent Bioscience Secures $21.5 Million Series B Financing to Advance Clinical Development of Tumor-Targeted Fluorescent Imaging Agent VGT-309. Read the full media release: https://t.co/TTwCUwzeVs #innovation #tumorvisualization

0:15